Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialAdrian F. Hernandez, Lauren B. Cooper, Lawrence A. Leiter et al.|The Lancet|2018Cited by 1.8k
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostateKenneth A. Iczkowski, David G. Bostwick, Jingxin Qiu et al.|Urology|2005Cited by 80
Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trialNeil Fleshner, Roger S. Rittmaster, Leonard G. Gomella et al.|Contemporary Clinical Trials|2007Cited by 68